

HIPERTENSIÓN PULMONAR SECUNDARIA A SEPSIS EN EL NEONATO

MARÍA PATRICIA YEPES PADILLA

C.C No1129519127

Código estudiantil: 2016213578332

Correo institucional: maria.yepes1@unisimon.edu.co

JHONY ALEXANDER BARRIOS QUINTERO

CC 1045710975

Código estudiantil: 2020213526944

Correo institucional: jhony.barrios@unisimon.edu.co

Trabajo de Investigación presentado como requisito para optar el título de:
ESPECIALISTA EN PEDIATRÍA

Tutores:

CESAR ANGULO GARCÍA
MD | PED | NEO

HENRY J GONZALEZ-TORRES

Bio | Spc App Stat | MSc Bio (GenPop) | PhD (c) BioMed

RESUMEN

La hipertensión pulmonar es un síndrome de falla respiratoria aguda caracterizado por elevación sostenida de las resistencias vasculares pulmonares (RVP), que produce hipertensión persistente de la arteria pulmonar después del nacimiento, que ocasiona cortocircuito extrapulmonar de derecha a izquierda de sangre no oxigenada a través del conducto arterioso (CA) y foramen oval (FO) con hipoxemia severa y acidosis secundaria. La hipertensión pulmonar secundaria a sepsis (HTP-S) es una de las complicaciones de mayor preocupación en los neonatos por las implicaciones que puede conllevar a corto, media y largo plazo, algunas incluso pudiendo a comprometer la vida del niño, por los compromisos a nivel renal, cardíaco y evidentemente respiratorio. La HTP-S puede explicarse por varios mecanismos; ejemplo: gérmenes comunes en la etapa neonatal como (*Streptococcus* del grupo B y bacterias gramnegativas), liberan endotoxinas bacterianas desencadenando una respuesta inflamatoria secundaria, con liberación de tromboxano endotelial y de varias citoquinas (como el factor de necrosis tumoral-alfa) que lleva a un aumento en las resistencias vasculares pulmonares. Aunque la HTP es una causa frecuente de ingreso a la Unidad de Cuidados intensivos neonatales, la causa que termina en hipertensión pulmonar puede pasar desapercibida ya sea por poca asociación a la patología o por su baja frecuencia, como es el caso de la HTP secundaria a sepsis, considerada como un desafío debido a la dificultad de identificar a los recién nacidos en riesgo de sepsis, especialmente a los que tienen un buen aspecto general.

Objetivo: Caracterización de la Hipertensión Pulmonar secundaria a Sepsis en el Neonato en una Unidad de Cuidados Intensivos Neonatales en Barranquilla (Atl, CO) entre los años 2021 – 2022.

Metodología: Se realizó un estudio tipo analítico, cuantitativo, retrospectivo. Se utilizó estadística descriptiva, se hicieron test de chi cuadrado y Exacto de Fisher para establecer las relaciones entre variables. Se llevo a cabo en una unidad de cuidados intensivos neonatales de la ciudad de Barranquilla.

Resultados: Se recolectaron en total 50 pacientes con diagnóstico de HTP-S. La edad global fue de 7,14 (IC 3.74 – 8.74) días, sin diferencia entre sexos ($p > 0.05$). El 52% de los pacientes tuvieron una edad gestacional a término. El 62% presentó HTP-S. Los pacientes prematuros tardíos y a término fueron lo que más presentaron HTP-S. Se encontró una asociación directamente proporcional entre el SDR y la HTP-S ($p: 0$). La manifestación más frecuente fue la Dificultad respiratoria (54.84%), las manifestaciones clínicas en los pacientes con sepsis que no desarrollaron HTP fueron más variadas e inespecíficas. En los pacientes con HTP-S la estancia fue mayor en un 23% (aproximadamente 10 días) ($p: 0.012$). Las bacterias Gram (+) fueron las de mayor representación, sin embargo, no se encontró diferencia significativa ($p > 0.05$). Se encontró una alta resistencia tipo de BLEA, meticilino resistente y resistencia a carbapenémicos, la cual no estuvo asociada al desarrollo de HTP-S, sin embargo, esta estuvo relacionada con la tasa de mortalidad.

Conclusión: La sepsis neonatal es una causa importante de hipertensión pulmonar, el alto porcentaje de HTP-S y su relación con la edad gestacional, aumento de estancia hospitalaria y múltiples manifestaciones clínicas, hace que el paciente con HTP-S tenga un riesgo elevado de mortalidad.

Palabras clave: Hipertensión secundaria a sepsis; Sepsis neonatal; Unidad de cuidados intensivos neonatal; Síndrome de Dificultad Respiratoria, Taquipnea; Mortalidad, antibiótico, resistencia antibiótica.

ABSTRACT

Pulmonary hypertension is a syndrome of acute respiratory failure characterized by sustained elevation of pulmonary vascular resistance (PVR), leading to persistent pulmonary artery hypertension after birth, leading to right-to-left extrapulmonary shunting of deoxygenated blood through the pulmonary artery. ductus arteriosus (CA) and foramen ovale (FO) with severe hypoxemia and secondary acidosis. Pulmonary hypertension secondary to sepsis (HTP-S) is one of the complications of greatest concern in neonates due to the implications that it may entail in the short, medium and long term, some of which may even compromise the life of the child, due to the commitments to renal, cardiac and obviously respiratory level. HTP-S can be explained by several mechanisms; example: common germs in the neonatal stage such as (group B Streptococcus and gram-negative bacteria), release bacterial endotoxins triggering a secondary inflammatory response, with release of endothelial thromboxane and several cytokines (such as tumor necrosis factor-alpha) that leads to an increase in pulmonary vascular resistance. Although PHT is a frequent cause of admission to the Neonatal Intensive Care Unit, the cause that ends in pulmonary hypertension may go unnoticed, either due to little association with the pathology or its low frequency, as is the case of PHT secondary to sepsis, considered a challenge due to the difficulty of identifying newborns at risk of sepsis, especially those with a good general appearance.

Objective: Characterization of Pulmonary Hypertension secondary to Sepsis in the Neonate in a Neonatal Intensive Care Unit in Barranquilla (Atl, CO) between the years 2021 - 2022.

Methodology: An analytical, quantitative, retrospective study was carried out. Descriptive statistics were used, chi-square and Fisher's exact tests were performed to establish the relationships between variables. It was carried out in a neonatal intensive care unit in the city of Barranquilla.

Results: A total of 50 patients diagnosed with HTP-S were collected. The overall age was 7.14 (CI 3.74 – 8.74) days, with no difference between sexes ($p > 0.05$). 52% of the patients had a gestational age at term. 62% presented HTP-S. Late and

term preterm patients were the ones that most presented HTP-S. A directly proportional association was found between SDR and HTP-S ($p: 0$). The most frequent manifestation was respiratory distress (54.84%), the clinical manifestations in patients with sepsis who did not develop PHT were more varied and nonspecific. In patients with HTP-S, the stay was longer by 23% (approximately 10 days) ($p: 0.012$). Gram (+) bacteria were the most represented, however, no significant difference was found ($p > 0.05$). A high type of ESBL resistance, resistant methicillin and resistance to carbapenems was found, which was not associated with the development of HTP-S, however, this was related to the mortality rate.

Conclusion: Neonatal sepsis is an important cause of pulmonary hypertension, the high percentage of PHT-S and its relationship with gestational age, increased hospital stay and multiple clinical manifestations, makes the patient with PHT-S have a high risk of mortality.

Keywords: Hypertension secondary to sepsis; Neonatal sepsis; Neonatal intensive care unit; Respiratory Distress Syndrome, Tachypnea; Mortality, antibiotic, antibiotic resistance.

REFERENCIAS BIBLIOGRÁFICAS

1. Alrowaily N, D'Souza R, Dong S, Chowdhury S, Ryu M, Ronzoni S. Determining the optimal antibiotic regimen for chorioamnionitis: A systematic review and meta-analysis. *Acta Obstet Gynecol Scand.* 2020; 15. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33191493>
2. Rafi MA, Miah MMZ, Wadood MA, Hossain MG. Risk factors and etiology of neonatal sepsis after hospital delivery: A case-control study in a tertiary care hospital of Rajshahi, Bangladesh. *PLoS One.* 2020;15(11):e0242275. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/33186407>
3. Cetinkaya M, Cekmez F, Buyukkale G, Erener-Ercan T, Demir F, Tunc T, et al. Lower vitamin D levels are associated with increased risk of early-onset neonatal sepsis in term infants. *J Perinatol.* 2015;35(1):39–45.

4. Méndez L, Osorio O, Contreras M, García Del villar O, Vence C, Barrios K. Pulmonary sequestration an uncommon cause of persistent pulmonary hypertension in the newborn case report. *Salud Uninorte*. 2017;33(3):532–7.
5. Ward PA. What's new in the quagmire of sepsis? *Trends Mol Med*. 2014;20(4):189–90.
6. Wu I-H, Tsai M-H, Lai M-Y, Hsu L-F, Chiang M-C, Lien R, et al. Incidence, clinical features, and implications on outcomes of neonatal late-onset sepsis with concurrent infectious focus. *BMC Infect Dis*. 2017;17(1):465.
7. Shane AL, Sánchez PJ, Stoll BJ. Neonatal sepsis. *Lancet*. 2017;390(10104):1770–80.
8. Good PI, Hooven TA. Evaluating Newborns at Risk for Early-Onset Sepsis. *Pediatr Clin North Am*. 2019;66(2):321–31.
9. Sola A, Mir R, Lemus L, Fariña D, Ortiz J. Suspected Neonatal Sepsis: Tenth Clinical Consensus of the Ibero-American Society of Neonatology (SIBEN). 2020;21(8).
10. Berberian G. SEPSIS NEONATAL. 2014;XXI.
11. Santos RP, Tristram D. A Practical Guide to the Diagnosis, Treatment, and Prevention of Neonatal Infections. *Pediatr Clin North Am*. 2015;62(2):491–508.
12. Yusef D, Shalakhti T, Awad S, Algharaibeh H, Khasawneh W. Clinical characteristics and epidemiology of sepsis in the neonatal intensive care unit in the era of multi-drug resistant organisms: A retrospective review. *Pediatr Neonatol*. 2018;59(1):35–41.
13. Wynn JL. Defining neonatal sepsis. *Curr Opin Pediatr*. 2016;28(2):135–40.
14. Huynh B-T, Padget M, Garin B, Delarocque-Astagneau E, Guillemot D, Borand L, et al. Bacterial neonatal sepsis and antibiotic resistance in low-income countries. *Lancet*. 2016;387(10018):533–4.
15. Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, Schlapbach LJ, Reinhart K, Kissoon N. The global burden of paediatric and neonatal sepsis: a systematic review. *Lancet Respir Med*. 2018;6(3):223–30.
16. Cecconi M, Evans L, Levy M, Rhodes A. Sepsis and septic shock. *Lancet*.

- 2018;392(10141):75–87.
17. Voller SMB, Myers PJ. Neonatal Sepsis. *Clin Pediatr Emerg Med.* 2016;17(2):129–33.
 18. Díaz Martín C, Marrero Pérez CL, Martín Fumero L, Torres Moreno A, de Quirós I. Early-onset *Streptococcus pneumoniae*-induced neonatal sepsis. *Arch Bronconeumol (English Ed.* 2020;56(10):671–2.
 19. Cortese F, Scicchitano P, Gesualdo M, Filaninno A, De Giorgi E, Schettini F, et al. Early and Late Infections in Newborns: Where Do We Stand? A Review. *Pediatr Neonatol.* 2016;57(4):265–73.
 20. Ferrieri P, Wallen YLD. 39 - Sepsis y meningitis en el recién nacido. Tenth Edit. Avery. *Enfermedades del recién nacido.* 2019. 553–565 p.
 21. Silva ACB, Anchieta LM, Lopes MF de P, Romanelli RM de C. Inadequate use of antibiotics and increase in neonatal sepsis caused by resistant bacteria related to health care assistance: a systematic review. *Brazilian J Infect Dis.* 2018;22(4):328–37.
 22. Rappaort R, Rotem R, Rottenstreich M, Kasirer Y, Grisaru-Granovsky S, Bin-Nun A, et al. 814: Chorioamnionitis and neonatal evaluation; universal evaluation for all? *Am J Obstet Gynecol.* 2020;222(1):S513.
 23. Ferreira J, Camargos PAM, Rosado V, Mourão PHO, Romanelli RM de C. Risk factors for central venous catheter-related bloodstream infection in neonates. *Am J Infect Control.* 2020;48(9):1102–3.
 24. Ferreira J, Camargos PAM, Clemente WT, Romanelli RM de C. Clinical usefulness of catheter-drawn blood samples and catheter tip cultures for the diagnosis of catheter-related bloodstream infections in neonatology: A systematic review. *Am J Infect Control.* 2018;46(1):81–7.
 25. Harrison GJ. Approach to infections in the fetus and newborn. Eighth Edi. Feigin and Cherry's textbook of pediatric infectious diseases. 2014. 877–901 p.
 26. Esper F. 48 - Postnatal Bacterial Infections. Eleventh E. Fanaroff and Martin's Neonatal-Perinatal Medicine. 2020: 789–808
 27. Scheel M, Perkins S. Hit or Miss? A Review of Early-Onset Sepsis in the

- Neonate. Crit Care Nurs Clin North Am. 2018;30(3):353–62.
28. Iroh Tam P-Y, Bendel CM. Diagnostics for neonatal sepsis: current approaches and future directions. *Pediatr Res*. 2017;82(4):574–83.
 29. Qiu X, Zhang L, Tong Y, Qu Y, Wang H, Mu D. Interleukin-6 for early diagnosis of neonatal sepsis with premature rupture of the membranes. *Medicine (Baltimore)*. 2018;97(47):e13146.
 30. Boskabadi H, Zakerihamidi M. Evaluate the diagnosis of neonatal sepsis by measuring interleukins: A systematic review. *Pediatr Neonatol*. 2018;59(4):329–38.
 31. Memar MY, Alizadeh N, Varshochi M, Kafil HS. Immunologic biomarkers for diagnostic of early-onset neonatal sepsis. *J Matern Neonatal Med*. 2019;32(1):143–53.
 32. Tzialla C, Manzoni P, Achille C, Bollani L, Stronati M, Borghesi A. New Diagnostic Possibilities for Neonatal Sepsis. *Am J Perinatol*. 2018;35(06):575–7.
 33. Sharma D, Farahbakhsh N, Shastri S, Sharma P. Biomarkers for diagnosis of neonatal sepsis: a literature review. *J Matern Neonatal Med*. 2018;31(12):1646–59.
 34. Chauhan N, Tiwari S, Jain U. Potential biomarkers for effective screening of neonatal sepsis infections: An overview. *Microb Pathog*. 2017;107:234–42.
 35. Rooney SP, Heffren JC, Song BL, Sanchez AC. Management of Sepsis in the Pediatric Patient. *J Radiol Nurs*. 2020;39(1):24–31.
 36. Mukhopadhyay S, Wade KC, Puopolo KM. Drugs for the Prevention and Treatment of Sepsis in the Newborn. *Clin Perinatol*. 2019;46(2):327–47.
 37. Molyneux E, Gest A. Neonatal sepsis: an old issue needing new answers. *Lancet Infect Dis*. 2015;15(5):503–5.
 38. Arias D, Narváez C. Atención al recién nacido con hipertensión pulmonar persistente. *Repert Med y Cirugía*. 2016;25(4):219–27.
 39. Limjoco J, Paquette L, Ramanathan R, Seri I, Friedlich P. Changes in Mean Arterial Blood Pressure During Sildenafil Use in Neonates With Meconium Aspiration Syndrome or Sepsis. *Am J Ther*. 2015;22(2):125–31.

40. Cabral JEB, Belik J. Persistent pulmonary hypertension of the newborn: recent advances in pathophysiology and treatment. *J Pediatr (Rio J)*. 2013;89(3):226–42.
41. Montasser M, Patel N. Pulmonary hypertension in newborn infants: pathophysiology, clinical assessment and management. *Paediatr Child Health (Oxford)*. 2021;31(1):32–7.
42. Prusakowski MK, Chen AP. Pediatric Sepsis. *Emerg Med Clin North Am*. 2017;35(1):123–38.
43. Calcaterra G, Bassareo PP, Barilla F, Martino F, Fanos V, Fedele F, et al. Pulmonary hypertension in pediatrics. A feasible approach to bridge the gap between real world and guidelines. *J Matern Neonatal Med*. 2019:1–7.
44. Sardar S, Pal S, Mishra R. A Retrospective study on the profile of persistent pulmonary hypertension of newborn in a tertiary care unit of Eastern India. *J Clin Neonatol*. 2020;9(1):18.
45. Tsai M-H, Hsu J-F, Chu S-M, Lien R, Huang H-R, Chiang M-C, et al. Incidence, Clinical Characteristics and Risk Factors for Adverse Outcome in Neonates With Late-onset Sepsis. *Pediatr Infect Dis J*. 2014;33(1):e7–13.
46. Tsai M-H, Wu IH, Lee C-W, Chu S-M, Lien R, Huang H-R, et al. Neonatal gram-negative bacillary late-onset sepsis: A case-control-control study on a prospectively collected database of 5,233 admissions. *Am J Infect Control*. 2016;44(2):146–53.
47. Jain A, McNamara PJ. Persistent pulmonary hypertension of the newborn: Advances in diagnosis and treatment. *Semin Fetal Neonatal Med*. 2015;20(4):262–71.
48. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, et al. Updated Clinical Classification of Pulmonary Hypertension. *J Am Coll Cardiol*. 2013;62(25):D34–41.
49. Hopper RK, Abman SH, Ivy DD. Persistent Challenges in Pediatric Pulmonary Hypertension. *Chest*. 2016;150(1):226–36.
50. Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, et al. Pediatric Pulmonary Hypertension. *Circulation*. 2015;132(21):2037–99.

51. Fuloria M, Aschner JL. Persistent pulmonary hypertension of the newborn. *Semin Fetal Neonatal Med.* 2017;22(4):220–6.
52. Baker CD, Abman SH, Mourani PM. Pulmonary Hypertension in Preterm Infants with Bronchopulmonary Dysplasia. *Pediatr Allergy Immunol Pulmonol.* 2014;27(1):8–16.
53. Wardle AJ, Tulloh RMR. Paediatric pulmonary hypertension and sildenafil: current practice and controversies. *Arch Dis Child - Educ Pract Ed.* 2013;98(4):141–7.
54. Keller RL. Pulmonary Hypertension and Pulmonary Vasodilators. *Clin Perinatol.* 2016;43(1):187–202.
55. Lynch TD, Laffey JG. Hipertensión Pulmonar - Silfenafil - Revisión Cochrane. *Anesthesiology.* 2017;104(2):382; author reply 383.
56. Márquez-González H, Ibarra-Ríos D, Jean-Tron MG, Barajas-Nava LA. Uso de sildenafil para la hipertensión pulmonar en neonatos. *Bol Med Hosp Infant Mex.* 2020;77(4):202–6.
57. Ivy DD, Abman SH, Barst RJ, Berger RMF, Bonnet D, Fleming TR, et al. Pediatric Pulmonary Hypertension. *J Am Coll Cardiol.* 2013;62(25):D117–26.
58. Robbins IM, Moore TM, Blaisdell CJ, Abman SH. National Heart, Lung, and Blood Institute Workshop. *Circulation.* 2012;125(17):2165–70.
59. Li J, Chen S, Yan Y, Hu Y, Wei J, Wu Q, et al. Identification and antimicrobial resistance of pathogens in neonatal septicemia in China—A meta-analysis. *Int J Infect Dis.* 2018;71(2018):89–93.
60. Al-Matary A, Heena H, AlSarheed AS, Ouda W, AlShahrani DA, Wani TA, et al. Characteristics of neonatal Sepsis at a tertiary care hospital in Saudi Arabia. *J Infect Public Health.* 2019;12(5):666–72.
61. Khan F. C-reactive Protein as a Screening Biomarker in Neonatal Sepsis. *J Coll Physicians Surg Pakistan.* 2019;29(10):951–3.
62. Seliem WA, Sultan AM. Etiology of early onset neonatal sepsis in neonatal intensive care unit – Mansoura, Egypt. *J Neonatal Perinatal Med.* 2018;11(3):323–30.
63. Hamer D, Mwananyanda L, Cowden C, Pierre C, Mwansa J, Lukwesa C, et al.

- Sepsis prevention in neonates in Zambia study: Impact of an infection prevention bundle on neonatal sepsis and mortality. *Int J Infect Dis.* 2018;73(2018):43.
64. Alcock G, Liley HG, Cooke L, Gray PH. Prevention of neonatal late-onset sepsis: a randomised controlled trial. *BMC Pediatr.* 2017;17(1):98.
 65. Ruan L, Chen G-Y, Liu Z, Zhao Y, Xu G-Y, Li S-F, et al. The combination of procalcitonin and C-reactive protein or presepsin alone improves the accuracy of diagnosis of neonatal sepsis: a meta-analysis and systematic review. *Crit Care.* 2018;22(1):316.
 66. Burga-Montoya G, Luna Muñoz C, Correa López LE. Factores de riesgo asociados a sepsis neonatal temprana en prematuros de un Hospital Nacional Docente Madre Niño, 2017. *Rev la Fac Med Humana.* 2019;19(3):35–42.